STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer's disease Therapeutic Research at the Clinical Trials in Alzheimer's Disease (CTAD) congress in Madrid on October 29. Professor Lannfelt received the award in recognition for his pioneering work in Alzheimer's disease, specifically his scientific discoveries and contribution to drug development.
Professor Lannfelt's groundbreaking research has played a significant role in the scientific progress made in the field over decades, leading to the development of lecanemab, a disease-modifying treatment for early Alzheimer's disease approved in the U.S., Japan, China, Great Britain and other countries.
"The search for treatments to give hope and help patients and families affected by Alzheimer's disease is what has driven me throughout my scientific career," said Professor Lars Lannfelt. "This field or research is in the midst of a paradigm shift driven by the development of treatments such as lecanemab, which has demonstrated meaningful benefits to patients in the large phase 3 trial Clarity AD using gold standard endpoints. Coupled with the introduction of new diagnostic methods, I am convinced that within a number of years, we will not only be able to slow the progression of the disease, but eventually also stop the disease process entirely.
" Professor Lars Lannfelt fou.